ABSTRACT
Yttrium-90 microsphere therapy, which has become more common in recent years, offers an effective and safe radionuclide treatment option in the treatment of primary and metastatic liver tumors. The success of the treatment is directly related to the multidisciplinary approach of Nuclear Medicine and Interventional Radiology specialists, correct patient selection and personalized treatment approach. This guideline has been prepared to guide current applications of Y-90 microsphere therapy.
References
1Salem R, Gordon AC, Mouli S, et al. Y90 Radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2016;151:1155-1163.e2.
2Riaz A, Gabr A, Abouchaleh N, et al. Radioembolization for hepatocellular carcinoma: statistical confirmation of improved survival in responders by landmark analyses. Hepatology 2018;67:873-883.
3Salem R, Gabr A, Riaz A, et al. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience. Hepatology 2018;68:1429-1440.
4Mazzaferro V, Sposito C, Bhoori S, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 2013;57:1826-1837. doi: 10.1002/hep.26014. Epub 2013 Mar 22. PMID: 22911442.
5Devcic Z, Rosenberg J, Braat AJ, et al. The efficacy of hepatic 90Y resin radioembolization for metastatic neuroendocrine tumors: a meta-analysis. J Nucl Med 2014;55:1404-1410.
6Saxena A, Bester L, Shan L, et al. A systematic review on the safety and efficacy of yttrium-90 radioemboliza-tion for unresectable, chemorefractory colorectal cancer liver metastases. J Cancer Res Clin Oncol 2014;140:537-547.
7Kennedy AS, Salem R. Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies. Cancer J 2010;16:163-175.
8Edeline J, Touchefeu Y, Guiu B, et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol 2019;6:51-59.
9Yttrium S-S. Resin microspheres [package insert]. North Sydney. Australia: SirTex Medical; 2013.
10Package Insert -TheraSphere® Yttrium-90 Glass Microspheres – Rev. 14. Biocompatibles UK Ltd, a BTG International group company.
11Giammarile F, Bodei L, Chiesa C, et al. Therapy, Oncology and Dosimetry Committees. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging 2011;38:1393-1406.
12Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 2007;68:13-23.
13Gil-Alzugaray B, Chopitea A, Iñarrairaegui M, et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology 2013;57:1078-1087.
14Poyanli A. Radioembolization: angiographic techniques, difficult cases Nucl Med Semin 2019;5:117-121.
15Louie JD, Kothary N, Kuo WT, et al. Incorporating cone-beam CT into the treatment planning for yttrium-90 radioembolization. J Vasc Interv Radiol 2009;20:606-613.
16Salem R, Thurston KG. Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J Vasc Interv Radiol 2006;17:1251-1278.
17Borggreve AS, Landman AJEMC, Vissers CMJ, et al. Radioembolization: is prophylactic embolization of hepaticoenteric arteries necessary? A systematic review. Cardiovasc Intervent Radiol 2016;39:696-704.
18Lewandowski RJ, Sato KT, Atassi B, et al. Radioembolization with 90Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol 2007;30:571-592.
19Liu DM, Salem R, Bui JT, et al. Angiographic considerations in patients undergoing liver directed therapy. J Vasc Interv Radiol 2005;16:911-935.
20Kallini JR, Gabr A, Kulik L, Salem R, Lewandowski RJ. The utility of unilobar technetium-99m macroaggregated albumin to predict pulmonary toxicity in bilobar hepatocellular carcinoma prior to yttrium-90 radioembolization. J Vasc Interv Radiol 2016;27:1453-1456.
21Sabet A, Ahmadzadehfar H, Muckle M, et al. Significance of oral administration of sodium perchlorate in planning liver-directed radioembolization. J Nucl Med 2011;52:1063-1607.
22Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry--standardization of nomenclature. J Nucl Med 2009;50:477-484.
23Gulec SA, Mesoloras G, Stabin M. Dosimetric techniques in 90Ymicrosphere therapy of liver cancer: the MIRD equations for dose calculations. J Nucl Med 2006;47:1209-1211.
24Vouche M, Lewandowski RJ, Atassi R, et al. Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol 2013;59:1029-1036.
25Salem R, Padia SA, Lam M, et al. Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging 2019;46:1695-1704. doi: 10.1007/s00259-019-04340-5. Epub 2019 May 16.
26Riaz A, Gates VL, Atassi B, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys 2011;79:163-71. doi: 10.1016/j.ijrobp.2009.10.062. Epub 2010 Apr 24. PMID: 20421150.
27Sirtex medical training manual, training program physicians and institutions. Sirtex Medical Limited, Australia. Available from: http://www.sirtex.com/usa/_data/page/549/TRN-US- 0320for20 US1.pdf
28Bozkurt MF. Radioembolization: personalized treatment and protection from side effects. Nucl Med Sem 2019:5:122-130.
29Cremonesi M, Chiesa C, Strigari L, et al. Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective. Front Oncol 2014;4:210. Published 2014 Aug 19.
30Garin E, Rolland Y, Laffont S, Edeline J. Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres. Eur J Nucl Med Mol Imaging 2016;43:559-575.
31Palard X, Edeline J, Rolland Y, et al. Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2018;45:392-401.
32Lau WY, Kennedy AS, Kim YH, et al. Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys 2012;82:401-407.
33Chan KT, Alessio AM, Johnson GE, et al. hepatotoxic dose thresholds by positron-emission tomography after yttrium-90 radioembolization of liver tumors: a prospective single-arm observational study. Cardiovasc Intervent Radiol 2018;41:1363-1372. doi: 10.1007/s00270-018-1949-5. Epub 2018 Apr 12.
34Garin E, Rolland Y, Edeline J, et al. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis. J Nucl Med 2015;56:339-346.
35Kappadath SC, Mikell J, Balagopal A, et al. Hepatocellular carcinoma tumor dose response after 90y-radioembolization with glass microspheres using 90y-spect/ct-based voxel dosimetry. Int J Radiat Oncol Biol Phys 2018;102:451-461.
36Chiesa C, Maccauro M, Romito R, et al. Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan. Quart J Nucl Med Mol Imaging 2011;55:168-197.
37Chiesa C, Mira M, Maccauro M, et al. Radioembolization of hepatocarcinoma with (90)Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology. Eur J Nucl Med Mol Imaging 2015;42:1718-1738.
38Sangro B, Martínez-Urbistondo D, Bester L, et al. Prevention and treatment of complications of selective internal radiation therapy: Expert guidance and systematic review. Hepatology 2017;66:969-982. doi: 10.1002/hep.29207. Epub 2017 Jul 27.
39Haste P, Tann M, Persohn S, et al. Correlation of technetium-99m macroaggregated albumin and yttrium-90 glass microsphere biodistribution in hepatocellular carcinoma: a retrospective review of pretreatment single photon emission ct and posttreatment positron emission tomography/CT. J Vasc Interv Radiol 2017;28:722-730.e1.
40Balagopal A, Kappadath SC. Characterization of 90 Y-SPECT/CT self-calibration approaches on the quantification of voxel-level absorbed doses following 90 Y-microsphere selective internal radiation therapy. Med Phys 2018;45:875-883.
41Yakupoglu A. Assessment of radioembolization treatment response: standardization, tips & tricks. Nucl Med Semin 2019;5:131-138.
42Atassi b, Bangash AK, Bahrani A, et al. Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay. Radiographics 2008;28:81-99.
